Literature DB >> 1939217

The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII.

R J Wise1, A J Dorner, M Krane, D D Pittman, R J Kaufman.   

Abstract

von Willebrand factor (vWF) is a multimeric glycoprotein that promotes platelet aggregation and stabilizes coagulation factor VIII in the plasma. vWF is also required for the stable accumulation of recombinant factor VIII secreted from cells in a heterologous expression system. In this report, we show that vWF can promote the in vitro reconstitution of factor VIII activity from dissociated heavy and light chains of factor VIII, suggesting that vWF may act to promote stable assembly of factor VIII subunits at the site of secretion. The structural requirements for vWF propeptide cleavage and for vWF multimerization in its binding and stabilization of factor VIII was examined using specifically altered recombinant vWF. The mutant vWF molecules were also assayed for their function in ristocetin-induced platelet agglutination mediated through the platelet receptor GPIb. Deletion of the vWF propeptide produced a dimeric vWF molecule that failed to mediate platelet agglutination, suggesting that multimerization is required for vWF to attain functional GPIb binding. This mature dimeric form of vWF, however, was fully capable of binding to and supporting stable secretion of factor VIII. A vWF mutant with an altered propeptide cleavage site formed large multimers of uncleaved pro-vWF that functioned in platelet agglutination. However, this noncleavage mutant neither bound to or supported stable accumulation of factor VIII. Analysis of the vWF propeptide, expressed independently, demonstrated that it could not bind factor VIII or stabilize its secretion. These results show that the dimeric mature vWF subunit is sufficient to bind and stabilize factor VIII and that the presence of uncleaved vWF propeptide inhibits both factor VIII binding and stabilization.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939217

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Correction of a murine model of von Willebrand disease by gene transfer.

Authors:  Robert G Pergolizzi; Guangchun Jin; Diane Chan; Lorraine Pierre; James Bussel; Barbara Ferris; Philip L Leopold; Ronald G Crystal
Journal:  Blood       Date:  2006-04-25       Impact factor: 22.113

2.  Effect of transmembrane pressure on Factor VIII yield in ATF perfusion culture for the production of recombinant human Factor VIII co-expressed with von Willebrand factor.

Authors:  Seung-Chul Kim; Sora An; Hyun-Ki Kim; Beom-Soo Park; Kyu-Heum Na; Byung-Gee Kim
Journal:  Cytotechnology       Date:  2015-10-13       Impact factor: 2.058

3.  pH-dependent association of factor VIII chains: enhancement of affinity at physiological pH by Cu2+.

Authors:  Hironao Wakabayashi; Qian Zhou; Keiji Nogami; Charles Ansong; Fatbardha Varfaj; Stephen Miles; Philip J Fay
Journal:  Biochim Biophys Acta       Date:  2006-04-22

4.  Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.

Authors:  Vivek S Purohit; Sathyamangalam V Balasubramanian
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

5.  Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage.

Authors:  A Preininger; U Schlokat; G Mohr; M Himmelspach; V Stichler; A Kyd-Rebenburg; B Plaimauer; P L Turecek; H P Schwarz; W Wernhart; B E Fischer; F Dorner
Journal:  Cytotechnology       Date:  1999-07       Impact factor: 2.058

6.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

Review 7.  Role of von Willebrand factor in the haemostasis.

Authors:  Flora Peyvandi; Isabella Garagiola; Luciano Baronciani
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

8.  BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.

Authors:  Ekta Seth Chhabra; Tongyao Liu; John Kulman; Susannah Patarroyo-White; Buyue Yang; Qi Lu; Douglas Drager; Nancy Moore; Jiayun Liu; Amy M Holthaus; Jurg M Sommer; Ayman Ismail; Deana Rabinovich; Zhan Liu; Arjan van der Flier; Allison Goodman; Chris Furcht; Mark Tie; Tyler Carlage; Randy Mauldin; Terrence M Dobrowsky; Zhiqian Liu; Oblaise Mercury; Lily Zhu; Baisong Mei; Volker Schellenberger; Haiyan Jiang; Glenn F Pierce; Joe Salas; Robert Peters
Journal:  Blood       Date:  2020-04-23       Impact factor: 22.113

9.  Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII.

Authors:  Andrew Yee; Austin N Oleskie; Anne M Dosey; Colin A Kretz; Robert D Gildersleeve; Somnath Dutta; Min Su; David Ginsburg; Georgios Skiniotis
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

10.  A prothrombin activator from Bothrops erythromelas (jararaca-da-seca) snake venom: characterization and molecular cloning.

Authors:  Márcia B Silva; Mirta Schattner; Celso R R Ramos; Inácio L M Junqueira-de-Azevedo; Míriam C Guarnieri; María A Lazzari; Claudio A M Sampaio; Roberto G Pozner; Janaina S Ventura; Paulo L Ho; Ana M Chudzinski-Tavassi
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.